Dallas-OncoNano Medicine, which is developing an imaging agent to help surgeons better remove tumors, has raised $11.7 million in Series A funding.
OncoNano’s lead product, ONM-100, is an injectable imaging agent that targets the acidic pH within tumors to better distinguish cancer cells from healthy ones during surgery.
OncoNano said the new funding was arranged by Salem Partners, which also participated as a principal investor. The round included institutional and individual investors that the company did not name. The new investment follows a $6 million grant the company received from the Cancer Prevention and Research Institute of Texas (CPRIT).
Ravi… Read more »
UNDERWRITERS AND PARTNERS